Increased incidence of co-trimoxazole-induced rash in patients on systemic corticosteroid treatment for toxicity associated with immune checkpoint inhibitors.

A study published in the British Journal of Dermatology found that 13% of patients developed a rash after receiving co-trimoxazole treatment while on immune checkpoint inhibitor (CPI) therapy. The severity of the rash was higher in this patient group, and they had a significantly shorter median overall survival compared to those who did not develop the rash. Prompt recognition and withdrawal of co-trimoxazole treatment is recommended in the context of CPI therapy. Further studies are needed to validate these findings and understand the mechanisms behind the increased incidence and severity of the rash. [Extracted from the article]